Merrimack Pharmaceutical Inc.

Cambridge, MA, United States

Merrimack Pharmaceutical Inc.

Cambridge, MA, United States

Time filter

Source Type

Patent
Merrimack Pharmaceutical Inc. | Date: 2016-06-03

Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to ErbB3 inhibitors, and methods of treating a cancer patient with targeted therapies.


Provided herein are compositions comprising anti-IGF-1R, anti-ErbB3 bispecific antibodies alone or in combination with other anti-cancer agents. Also provided are methods of treating a subject having cancer and methods for determining whether a patient with cancer is likely to respond to the compositions described herein.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-11-01

The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.


Patent
Merrimack Pharmaceutical Inc. | Date: 2017-05-31

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-12-09

Provided are methods for treating breast cancer in a patient by administering effective amounts of liposomal irinotecan sucrosofate (MM-398). The breast cancer may be triple negative breast cancer (TNBC), estrogen receptor/progesterone receptor (ER/PR) positive breast cancer, ER-positive breast cancer, or PR-positive breast cancer, or metastatic breast cancer.


Provided herein are compositions comprising anti-IGF-lR, anti-ErbB3 bispecific antibodies alone or in combination with other anti-cancer agents. Also provided are methods of treating a subject having cancer and methods for determining whether a patient with cancer is likely to respond to the compositions described herein.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-08-30

Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.


Patent
Merrimack Pharmaceutical Inc. | Date: 2017-01-11

A liposome-encapsulated formulation of irinotecan can be used for the treatment of pancreatic cancer in combination with 5-fluorouracil and leucovorin, including treatment of patients diagnosed with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-12-07

Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-12-09

Provided herein are tandem Fcs and tandem Fc antibodies (TFcAs), e.g., tandem Fc bispecific antibodies (TFcBAs), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.

Loading Merrimack Pharmaceutical Inc. collaborators
Loading Merrimack Pharmaceutical Inc. collaborators